Thursday, 23 April 2020

Interlukin 6 Antagonist



Interlukin - 6 



IL - 6 and Systemic Effects 




IL - 6 Inflammatory Pathways



IL -6 Disease Association: Atherosclerosis/Leukemia/COPD/Arthritis 



Agents Targeting IL -6 Pathway




Tocilizumab/Sarilumab Indicated For Rheumatoid Arthritis



Tocilizumab 






Tocilizumab in Rheumatoid Arthritis 





Current Events 

IL - 6 Storm 

Tocilizumab may be effective for patients with COVID-19, blood cancer


The immunosuppressant tocilizumab may be an effective treatment for very ill individuals with COVID-19 and hematologic malignancies, according to results of a case study from China published in Blood Advances.
Early research suggests the novel coronavirus triggers an excessive immune response and “a strong cytokine storm” that may include high levels of interleukin-6 and granulocyte-macrophage colony-stimulating factor, according to study background.


                                                           Snapshot

                                      Tocilizumab For Interlukin Storm 




























No comments:

Post a Comment